Fundraising Fox
Intrommune
New York City, US · 2 known investors
Find your way into Intrommune
Each arrow is one introduction. Sign up to fill in the first one.
362 people can intro you to Miles
Ask Jim Caggiano to introduce you to Miles McLennan
You →Jim · together at Allergan →Miles
69 people can intro you to William
Ask Jamie Chen to introduce you to William E. Berger
You →Jamie · together at University of California, Irvine - The Paul Merage School of Business →William
Sign up to find every way you can get introduced to Intrommune
- Your email: who you already know at Intrommune, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Intrommune team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
Founders & leadership
WE
William E. BergerHead of Medical AffairsWilliam E. Berger received his MD from the University of Cincinnati College of Medicine in 1973 and completed pediatrics residency and allergy-immunology fellowship training at UCLA Medical Center and National Jewish Hospital respectively. He founded the Allergy and Asthma Associates of Southern California in 1981, established a clinical research center in 1995, earned an MBA from UC Irvine in 1997, and held faculty appointments at UC Irvine before joining Intrommune in 2022 as Head of Medical Affairs.
CR
Christopher R. SchusterChief Financial Officer
NM
Nandini MurthyHead of Regulatory
RF
Ray ForslundHead of Chemistry, Manufacturing and Controls
MM
Miles McLennanHead of Commercial & Clinical OperationsMiles McLennan is Head of Commercial & Clinical Operations at Intrommune, a biotechnology company developing oral mucosal immunotherapy delivered through toothpaste to treat food allergies. He brings over 30 years of experience in pharmaceutical sales, marketing, and clinical operations, with a background in leading teams and managing new product development and commercialization programs.
Investors · 2
Related companies · 7
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
NexImmuneNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
EvommuneEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Primmune TherapeuticsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
AvammuneAvammune is a biotech company developing novel therapeutic modalities to address hard-to-treat cancers with distinct mechanisms of action. The company focuses on patient-centric oncology drug discovery, emphasizing improved compliance, ease of administration, and greater accessibility.
Inmune BioINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Companies working in the same space as Intrommune.
Frequently asked questions
- What does Intrommune do?
- Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
- Who are Intrommune's investors?
- Intrommune's investors include Red Bear Angels, Robin Hood Ventures.
- Where is Intrommune headquartered?
- Intrommune is headquartered in New York City, US.